NCT02166944

Tamoxifen Treatment in Patients With Motor Neuron Disease

The Study of Tamoxifen Treatment in Patients With Motor Neuron Disease

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Taipei Medical University Shuang Ho Hospital · Academic / Other
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to survey the effect of Tamoxifen in motor neuron disease (MND) patients, amyotrophic lateral sclerosis (ALS) with regular riluzole usage. TDP-43 is related to ALS. Increased the ubiquitinated or phosphorylated TDP-43 can cause animal model of ALS, and TDP43 can be degraded either by proteasome or autophagy pathway system. Autophagy pathway can be activated by mTOR inhibition, resulting in ameliorating TDP-43 accumulation and rescue in motor function in animal model. Tamoxifen had shown ability of enhance both proteasome and autophagy pathway, therefore the investigators assume that Tamoxifen probably can ameliorate TDP-43 accumulation and inclusion body formation in ALS.

Detailed description

The investigators will assess the ALSFR-s in ALS patients at start, 1, 3, 6 and 12 months and correlate the score to the neurological outcome of the patients with and without tamoxifen treatment at dose of 40mg daily for one year. The study will be able to prove the investigators hypothesis: Tamoxifen, a protease and autophagy enhancer, has synergic effect with riluzole in ALS patients to slowing the progression of neurological dysfunction, and respiratory insufficiency.

Conditions

• Amyotrophic Lateral Sclerosis
• ALS Functional Ration Scale
• TAR-DNA-binding Protein-43
• Tamoxifen
• mTOR

Interventions

Type	Name	Description
DRUG	tamoxifen 40 mg daily for one year	both arms with riluzole daily

Timeline

• Start date: 2014-04-01
• Primary completion: 2019-09-17
• Completion: 2019-09-18
• First posted: 2014-06-18
• Last updated: 2019-09-19

Locations

1 site across 1 country: Taiwan